Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1453-1456

  Craig, Benjamin M ^a   Rollison, Dana E ^a   List, Alan F ^a   Cogle, Christopher R ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer registry; ESAs; MDS incidence; SEER Medicare data; Testing, treatment and survival

Indexed keywords

ANTIANEMIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALGORITHM; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HEALTH CARE COSTS; HEMATINICS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEDICARE; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 80053971998     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.028     Document Type: Article

References (14)

1. Sant M., Allemani C., Tereanu C., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116:3724-3734.
2. Steensma D.P. Myelodysplastic syndromes: pathobiology and clinical management 2008, Informa Healthcare. 2nd ed.
3. Ma X., Does M., Raza A., et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
4. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
5. Cogle C.R., Craig B.M., Rollison D.E., et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011.
6. Goldberg S.L., Chen E., Corral M., et al. Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries. J Clin Oncol 2010, 28:2847-2852.
7. Warren J.L., Klabunde C.N., Schrag D., et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40. pp. IV-3-18.
8. Foundation THJKF. Medicare+Choice Fact Sheet. April 2003 ed.; 2003.
9. Foundation THJKF. Medicare Advantage FactSheet; 2004.
10. Foundation THJKF. Medicare Advantage Factsheet; 2005.
11. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
12. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
13. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
14. Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res, in press.